Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STSA-1002 in viral pneumonia-associated acute respiratory distress syndrome
CTR20232868Phase 2Completed
- Sponsor
- Staidson Biopharmaceutical
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of STSA-1002 in acute respiratory distress syndrome (ARDS), sponsored by Staidson Biopharmaceutical. Started Sep 2023; status: completed.
02
Drugs
STSA-1002
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on CTR20232868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232868.